Pulse Pressure Not Mean Pressure Determines Cardiovascular Risk in Older Hypertensive Patients

Jacques Blacher, MD; Jan A. Staessen, MD, PhD; Xavier Girerd, MD; Jerzy Gasowski, MD; Lutgarde Thijs, BSc; Lisheng Liu, MD; Ji G. Wang, MD; Robert H. Fagard, MD; Michel E. Safar, MD

Background: Current guidelines for the management of hypertension rest almost completely on the measurement of systolic and diastolic blood pressure. However, the arterial blood pressure wave is more correctly described as consisting of a pulsatile (pulse pressure) and a steady (mean pressure) component.

Objective: To explore the independent roles of pulse pressure and mean pressure as determinants of cardiovascular prognosis in older hypertensive patients.

Methods: This meta-analysis, based on individual patient data, pooled the results of the European Working Party on High Blood Pressure in the Elderly trial (n = 840), the Systolic Hypertension in Europe Trial (n = 4695), and the Systolic Hypertension in China Trial (n = 2394). The relative hazard rates associated with pulse pressure and mean pressure were calculated using Cox regression analysis, with stratification for the 3 trials and with adjustments for sex, age, previous cardiovascular complications, smoking, and treatment group.

Results: A 10-mm Hg wider pulse pressure increased the risk of major cardiovascular complications; after controlling for mean pressure and the other covariates, the increase in risk ranged from approximately 13% for all coronary end points (P = .02) to nearly 20% for cardiovascular mortality (P = .001). In a similar analysis, mean pressure predicted the incidence of cardiovascular complications but only after removal of pulse pressure as an explanatory variable from the model. Furthermore, the probability of a major cardiovascular end point increased with higher systolic blood pressure; at any given level of systolic blood pressure, it also increased with lower diastolic blood pressure, suggesting that the wider pulse pressure was driving the risk of major complications.

Conclusions: In older hypertensive patients, pulse pressure not mean pressure is the major determinant of cardiovascular risk. The implications of these findings for the management of hypertensive patients should be further investigated in randomized controlled outcome trials in which the pulsatile component of blood pressure is differently affected by antihypertensive drug treatment.

Arch Intern Med. 2000;160:1085-1089

From the Service de Médecine Interne, Hôpital Broussais, Paris, France (Drs Blacher, Girerd, and Safar); Hypertension en Cardiovasculaire Revalidatie Eenheid, Departement Moleculair en Cardiovasculair Onderzoek, Katholieke Universiteit Leuven, Leuven, Belgium (Drs Staessen, Gasowski, and Fagard and Ms Thijs); and Hypertension Division, Cardiovascular Institute and Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People’s Republic of China (Drs Liu and Wang).

ARTERIAL HYPERTENSION mechanically stresses the endothelium and the deeper layers of the arterial wall. The ensuing arterial lesions lead in the long run to debilitating and lethal complications, in particular stroke and myocardial infarction. The current guidelines for the management of hypertension rest almost completely on the measurement of systolic and diastolic blood pressure, 2 specific inflection points of the blood pressure wave, which are usually considered in isolation.1,2 However, blood pressure propagates through the arterial tree as a repetitive continuous wave and is more accurately described as consisting of a pulsatile component (pulse pressure) and a steady component (mean pressure).3 The former depends on ventricular ejection, arterial stiffness, and the timing of wave reflections, whereas cardiac output and peripheral vascular resistance are the major determinants of mean pressure.

Several observational studies4-13 produced evidence suggesting that in middle-aged and older people pulse pressure may be a better predictor of cardiovascular complications than mean pressure. However, these findings require further clarification. Pulse pressure widens with advancing age,14 so the outcome trials in elderly hypertensive patients may provide a database particularly suitable to explore the independent roles of pulse pressure and mean pressure as determinants of cardiovascular prognosis. To address this issue with sufficient statistical power, the present study pooled the results of 3 placebo-controlled trials in elderly patients with hypertension: the European Working Party on High
STUDY PROTOCOLS

The EWPHE, Syst-Eur, and Syst-China had a placebo-controlled, parallel-group design, which is described in detail elsewhere.\textsuperscript{15-17} Eligible patients had to be at least 60 years old. During a 3-month run-in period using single-blind placebo, the patients were required to have average sitting systolic and diastolic blood pressures as follows: 160 to 239 mm Hg systolic and 90 to 119 mm Hg diastolic in the EWPHE\textsuperscript{15} and 160 to 219 mm Hg systolic and less than 95 mm Hg diastolic in Syst-Eur\textsuperscript{16} and Syst-China.\textsuperscript{17}

Before randomization\textsuperscript{15,16} or alternate allocation\textsuperscript{17} to double-blind treatment with active medication or placebo, the patients were stratified by center, sex, and cardiovascular complications in each of the 3 trials\textsuperscript{15-17} and in addition by age in the EWPHE.\textsuperscript{15} Active treatment was initiated with a fixed combination of hydrochlorothiazide plus triamterene (25 mg plus 50 mg, respectively, once or twice daily) in the EWPHE\textsuperscript{15} and with nitrindipine (10–40 mg/d) in Syst-Eur\textsuperscript{16} and Syst-China.\textsuperscript{17} In treatment-resistant patients, the first-line drug was combined with methyldopa (0.25–2 g/d) in the EWPHE,\textsuperscript{15} with enalapril maleate (5–20 mg/d) and/or hydrochlorothiazide (12.5–23 mg/d) in Syst-Eur,\textsuperscript{16} or with captopril (12.5–50 mg/d) and/or hydrochlorothiazide (12.5–30 mg/d) in Syst-China.\textsuperscript{17} The patients in the control groups received matching placebos.

In the 3 trials, systolic and phase V diastolic blood pressure were measured after at least 3 minutes of rest in the sitting position at 2 to 3 different visits during the placebo run-in period.\textsuperscript{15-17} The baseline blood pressure was defined as the average of all sitting readings obtained during the run-in period. Pulse pressure was the difference between systolic and diastolic blood pressures. Mean pressure was calculated as diastolic blood pressure plus one third of pulse pressure. In the present analysis, the definition of events was the same for the 3 trials. Thus, the end points reported in the present analysis did not include those classified as nonfatal, nonmorbid in the EWPHE.

STATISTICAL ANALYSIS

Database management and statistical analysis were performed with SAS software, version 6.12 (SAS Institute Inc, Cary, NC). Event rates in the tertiles of the pulse pressure distributions were compared with 2-tailed tests by computing the standardized normal deviate. Pulse pressure and mean pressure were correlated with morbidity and mortality using the Cox proportional hazards model. Stratification of the Cox model accounted for the differences among the 3 trials. The data were analyzed by intention to treat for all end points, with the exception of the nonfatal complications in the EWPHE, which had only been recorded during the double-blind phase of this study.

RESULTS

CARDIOVASCULAR END POINTS IN TERTILES OF PULSE PRESSURE

The main characteristics of the patients enrolled in the EWPHE, Syst-Eur, and Syst-China appear in Table 1. Overall, pulse pressure ranged from 42 to 154 mm Hg and mean pressure from 80 to 157 mm Hg. In a first step of the analysis, the crude incidence rates of all fatal and nonfatal cardiovascular end points were calculated in tertiles of pulse pressure in the 2 treatment groups of each of the 3 trials separately (Figure 1). In all instances, with the exception of the placebo group in Syst-Eur (P = .20), the occurrence of all fatal and nonfatal cardiovascular end points was significantly greater in the highest compared with the lowest tertile of pulse pressure.

PULSE PRESSURE AND MEAN PRESSURE AS INDEPENDENT RISK FACTORS

In a further step of the analysis, the risks associated with pulse pressure and mean pressure were adjusted for sex, age, previous cardiovascular complications, smoking, and active treatment. In addition, the relative hazard rates for pulse pressure were also adjusted for mean pressure and vice versa (Table 2). In each trial, with the exception of only the coronary end points in Syst-Eur, pulse pressure was associated with a risk ratio greater than unity; the hazard rates were statistically significant for cardiovascular mortality and all cardiovascular end points in the EWPHE, for fatal and nonfatal stroke in Syst-Eur, and for all end points considered in the analysis in Syst-China. Overall, in Cox regression with stratification for the 3 trials and with adjustment for the other covariates,
a 10-mm Hg wider pulse pressure was correlated with an increase in the risk of any end point by approximately 10% to 20% (Table 2).

Mean pressure adjusted for pulse pressure and the same set of possible confounders was not identified as a consistent and significant predictor of risk (Table 2). However, without the adjustment for pulse pressure, the hazard rates associated with a 10-mm Hg increase in mean pressure were 1.16 (95% confidence interval [CI], 1.03-1.32; \( P = .02 \)) for total mortality, 1.17 (95% CI, 0.99-1.38; \( P = .06 \)) for cardiovascular mortality, 1.09 (95% CI, 0.98-1.27; \( P = .12 \)) for all cardiovascular end points, 1.21 (95% CI, 1.00-1.44; \( P = .05 \)) for fatal and nonfatal stroke, and 1.08 (95% CI, 0.89-1.32; \( P = .44 \)) for fatal and nonfatal coronary end points.

Pulse pressure and mean pressure were both calculated from systolic and diastolic blood pressure. To exclude the possibility that a mathematical artifact in these calculations led to the identification of pulse pressure rather than mean pressure as an independent risk factor, continuous risk functions were plotted for systolic blood pressure at fixed levels of diastolic blood pressure (Figure 2). The 2-year probability of a major cardiovascular end point increased with higher systolic blood pressure (\( P < .001 \)). However, at any given level of systolic blood pressure, the risk also increased (\( P = .001 \)) with lower diastolic blood pressure, suggesting that the wider pulse pressure was driving the risk of major complications.

**COMMENT**

The major finding of this study was that across 3 outcome trials involving older patients with systolic and diastolic hypertension13 or patients with isolated systolic hypertension,16-18 pulse pressure at entry—not mean pressure—individually predicted the incidence of cardiovascular complications and all-cause mortality. These results were consistent in white and Asian patients. Adjustments for active antihypertensive drug treatment and other possible confounders did not remove the relationship with pulse pressure. On the other hand, the present findings must be cautiously interpreted. The positive and independent correlation between pulse pressure and the incidence of cardiovascular complications does not necessarily imply a causal or reversible relationship. In addition, whether the present findings may be extrapolated to younger or middle-aged patients remains to be elucidated.

The Hypertension Detection and Follow-up Program reported that all-cause mortality increased by 11% per 10-mm Hg increment in pulse pressure but only by 8% and 5% for similar increases in systolic and diastolic blood pressures, respectively.19 The Framingham Heart Study demonstrated that in the general population systolic blood pressure was a better predictor of cardiovascular risk than diastolic blood pressure, particularly for patients older than 50 years,20 and that at any level of entry diastolic blood pressure, cardiovascular risk increased with systolic blood pressure. Similar findings were reported in a large cohort of middle-aged white men.5,13 Darne et al3 were among the first to notice that pulse pressure, in addition to mean pressure, was an independent cardiovascular risk factor, mainly for cardiac mortality, although only in women older than 55 years. More recently, several groups confirmed that pulse pressure in both hypertensive subjects7-10 and patients who had had myocardial infarctions11 predicted coronary events and, to a lesser extent, stroke. These findings were consistent in men and women and even in treated hypertensive patients whose diastolic blood pressure was reduced to within the normal range.8-10

In the present analysis, the 2-year probability of a major cardiovascular end point increased with higher systolic blood pressure. In addition, extrapolation from the Cox regression model showed that at any given level of systolic blood pressure the cardiovascular risk also in-
component of blood pressure, significantly improves the prediction of cardiovascular complications. For myocardial infarction, the underlying mechanism is not just the poor coronary perfusion associated with low diastolic blood pressure but also the generally reduced elasticity of the large arteries, which is a harbinger of vascular complications in all arterial beds. The repercussions of these findings for the diagnosis and management of hypertensive patients should be further investigated in randomized controlled clinical trials. In these future intervention studies, patients could be recruited on the basis of both the level of blood pressure and the width of pulse pressure. They could then be randomized to antihypertensive drugs, which act differently on the pulsatile component of blood pressure. Vasopeptidase inhibitors and nitric oxide donors may possibly increase the distensibility of the large arteries and reduce pulse pressure, although their hypothesized benefit in terms of a reduction of cardiovascular morbidity and mortality still remains to be proven.

Accepted for publication June 29, 1999.

This study was supported in part by the Société Française d'Hypertension Artérielle and by the Groupe de Pharmacologie et d'Hémodynamique Cardiovasculaire (Paris, France). The EWPHE and Syst-Eur were initiated by the late Prof A. Amery. The EWPHE was carried out in consultation with the World Health Organization and supported by the Belgian National Research Foundation and the Belgian Hypertension Committee through grants from Merck, Sharp and Dohme (West Point, Pa) and Smith-Kline and French (Brentford, England). Syst-Eur was a concerted action of the BIOMED Research Program sponsored by the European Union. Syst-Eur was carried out in consultation with the World Health Organization, the International Society of Hypertension, the European Society of Hypertension, and the World Hypertension League and supported by Bayer (Wuppertal, Germany). Syst-China was conducted under the auspices of State Commission of Sci-

## Table 2. Adjusted Relative Hazard Rates Associated With a 10-mm Hg Increase in Pulse or Mean Pressure

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>EWPHE</th>
<th>Syst-Eur</th>
<th>Syst-China</th>
<th>All†</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pulse pressure‡</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total mortality</td>
<td>1.09 (0.97-1.23)</td>
<td>1.06 (0.96-1.17)</td>
<td>1.38 (1.23-1.57)</td>
<td>1.15 (1.07-1.22)</td>
</tr>
<tr>
<td>Cardiovascular mortality</td>
<td>1.17 (1.01-1.36)</td>
<td>1.10 (0.97-1.27)</td>
<td>1.48 (1.27-1.72)</td>
<td>1.22 (1.13-1.33)</td>
</tr>
<tr>
<td>Cardiovascular endpoints</td>
<td>1.15 (1.03-1.29)</td>
<td>1.06 (0.97-1.16)</td>
<td>1.38 (1.24-1.55)</td>
<td>1.17 (1.10-1.24)</td>
</tr>
<tr>
<td>Stroke</td>
<td>1.10 (0.90-1.36)</td>
<td>1.16 (0.93-1.36)</td>
<td>1.22 (1.04-1.41)</td>
<td>1.17 (1.07-1.29)</td>
</tr>
<tr>
<td>Coronary endpoints</td>
<td>1.08 (0.90-1.32)</td>
<td>0.97 (0.83-1.12)</td>
<td>1.64 (1.36-2.00)</td>
<td>1.13 (1.02-1.24)</td>
</tr>
<tr>
<td>Mean pressure§</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total mortality</td>
<td>1.16 (0.94-1.44)</td>
<td>1.02 (0.83-1.23)</td>
<td>0.83 (0.65-1.04)</td>
<td>1.01 (0.90-1.14)</td>
</tr>
<tr>
<td>Cardiovascular mortality</td>
<td>1.22 (0.93-1.58)</td>
<td>0.89 (0.68-1.15)</td>
<td>0.72 (0.53-0.99)</td>
<td>0.97 (0.83-1.13)</td>
</tr>
<tr>
<td>Cardiovascular endpoints</td>
<td>1.12 (0.90-1.37)</td>
<td>0.93 (0.78-1.12)</td>
<td>0.83 (0.66-0.93)</td>
<td>0.96 (0.86-1.08)</td>
</tr>
<tr>
<td>Stroke</td>
<td>1.51 (1.05-2.18)</td>
<td>0.98 (0.74-1.31)</td>
<td>0.85 (0.63-1.15)</td>
<td>1.06 (0.89-1.27)</td>
</tr>
<tr>
<td>Coronary endpoints</td>
<td>1.09 (0.77-1.55)</td>
<td>1.05 (0.78-1.41)</td>
<td>0.76 (0.52-1.14)</td>
<td>0.97 (0.80-1.18)</td>
</tr>
</tbody>
</table>

*EWPHE indicates European Working Party on High Blood Pressure in the Elderly trial‡; Syst-Eur, Systolic Hypertension in Europe Trial§; and Syst-China, Systolic Hypertension in China Trial. All hazard rates are presented with 95% confidence intervals in parentheses and were adjusted for sex, age, previous cardiovascular complications, smoking, and active treatment.

†Stratification of the Cox models accounted for differences among the 3 trials.
‡Also adjusted for pulse pressure.
§Also adjusted for mean pressure.
¶P < .05.
¶¶P < .001.

![Figure 2. Risk associated with increasing systolic blood pressure at fixed levels of diastolic blood pressure. The 2-year probability of a cardiovascular end point was adjusted for active treatment, sex, age, previous cardiovascular complications, and smoking by Cox multiple regression with stratification for trial (European Working Party on High Blood Pressure in the Elderly trial, Syst-Eur Hypertension in Europe Trial, and Systolic Hypertension in China Trial).](image-url)
ence and Technology and the Public Health Ministry of the People's Republic of China. Syst-China was financially supported by the Chinese State Planning Commission and carried out in consultation with the World Health Organization and the World Hypertension League.

We gratefully acknowledge the expert help of the staff of the Syst-Eur Coordinating Office, Laboratory of Hypertension, Campus Gasthuisberg, University of Leuven, Leuven, Belgium: Nicole Ausseloos, Veerle Boon, Lut De Pauw, RN, Paul Drent, RN, Heng Fan, Yvette Piccart, Yvette Toremans, Sylvia Van Hulle, RN, and Renilde Wolfs.

Reprints: Jan A. Staessen, MD, PhD, Study Coordinating Center, the Hypertension and Cardiovascular Rehabilitation Unit, Department of Molecular and Cardiovascular Research, Campus Gasthuisberg, University of Leuven, Herestraat 49, B3000 Leuven, Belgium (e-mail: jan.staessen@med.kuleuven.ac.be).

REFERENCES


